Background: This phase II study evaluated the feasibility and efficacy of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer (MBC). Results: For both regimens, the median number of cycles administered was the maximum of eight. The alternating and sequential groups achieved similar objective tumor response rates (60% and 67%, respectively) and similar median duration of response (47 and 44 weeks, respectively). With a median follow-up of 31 months, median survival times were estimated at 20 and 26 months in the alternating and sequential groups, respectively. No unexpected toxicities were reported. Compared with alternating therapy, patients receiving sequential therapy were more likely to complete the planned eight chemotherapy cycles (69% versus 63%), and had a lower incidence of febrile neutropenia (2% versus 14%).
Introduction
Breast cancer is a leading contributor to cancer deaths worldwide [1, 2] . Chemotherapy plays an increasing role in the curative and palliative treatment of this disease. Anthracyclines remain the mainstay of treatment for metastatic breast cancer (MBC), either as monotherapy or in combination with other agents such as fluorouracil and/or cyclophosphamide [3] [4] [5] .
The taxanes, paclitaxel and docetaxel, are a newer class of chemotherapeutic agents that block tubulin depolymerization and thereby disrupt mitosis. They are among the most active cytotoxic agents available for the treatment of MBC [6] and have already led to improved therapeutic results in this disease, both in the palliative and adjuvant settings [7] [8] [9] [10] [11] [12] [13] . Docetaxel (Taxotere ® ), a semi-synthetic taxoid, has produced impressive response rates (48-68%) as single-agent first-line chemotherapy for MBC [12, [14] [15] [16] , and achieved the highest activity, to date, in women with disease resistant to anthracyclines [17] [18] [19] . Furthermore, in patients with prior exposure to alkylating-agent-based chemotherapy, docetaxel 100 mg/m 2 was shown to produce statistically superior response rates compared with doxorubicin 75 mg/m 2 (48% versus 33%; P = 0.008) [16] .
To further improve response rates and time to progression, combination regimens based on docetaxel and anthracyclines are being evaluated [20] [21] [22] . For example, in a phase II study, firstline docetaxel and doxorubicin combination therapy produced a high objective response rate of 76% [21] . However, to date, the best strategy for combining taxanes and anthracyclines (i.e. sequential versus concomitant versus alternating) has not been established by a single completed phase III study in patients with MBC, although this is an area of active investigation [23] [24] [25] .
Doses in combination regimens are generally limited by the combined toxicity profiles of the agents. The recommended combination doses for docetaxel and doxorubicin of 75 mg/m 2 and 50 mg/m 2 , respectively, are somewhat lower than those recommended for single-agent chemotherapy (100 mg/m 2 and 75 mg/m 2 , respectively), and have been defined based on grade 3 infection (the dose-limiting toxicity for this combination). Alternative strategies to deliver high doses of multiple chemotherapeutic agents in women with MBC are therefore currently being explored. Goldie and Coldman hypothesized that, since treatment failure is largely due to resistance to chemotherapy, and resistance develops by spontaneous random mutation at a rate proportional to the number of dividing cells, administering high doses of chemotherapy would rapidly reduce the number of dividing cells, thereby preventing resistance [26, 27] . Alternating high doses of non-cross-resistant agents on a cycle-by-cycle basis would minimize the emergence of double resistance. A second strategy is to administer multiple agents sequentially. A model proposed by Norton and Simon argued that rate of tumor regression is directly related to tumor growth rate [28, 29] , and that in a heterogeneous tumor, faster dividing cell populations would regress more quickly in response to chemotherapy than slower dividing cell populations. Norton and Simon hypothesized that the best management strategy would be to treat the faster dividing cell populations first, and then the slower dividing cell populations. This would be accomplished most efficiently by sequential chemotherapy with multiple cycles of one agent followed by multiple cycles of a second agent devoid of crossresistance with the first. Support for sequential chemotherapy can be found in a randomized study conducted in women with breast cancer who had more than three positive lymph nodes. The study found that patients receiving sequential doxorubicin then CMF (cyclophosphamide, methotrexate and 5-fluorouracil) had significantly (P = 0.002) improved survival and relapse-free survival rates 10 years post-surgery compared to those treated with alternating doxorubicin and CMF [4] .
In this paper, we report the results of an open-label randomized phase II study conducted to evaluate the feasibility, activity and tolerability of alternating and sequential regimens of docetaxel and doxorubicin administered as first-line chemotherapy for MBC.
Patients and methods
This open-label, randomized phase II study was conducted at 18 centers in nine countries (Austria, Belgium, Canada, France, Germany, Greece, The Netherlands, Israel, South Africa) between August 1996 and March 1998. The study was run in accordance with the Declaration of Helsinki, in compliance with local regulations, and with the approval of an independent Ethics Committee. All participants gave written or witnessed oral informed consent.
Inclusion/exclusion criteria
The study was open to women aged 18-75 years with histologically or cytologically proven breast cancer requiring first-line chemotherapy for progressive metastatic disease. Patients with a single metastatic lesion required histological or cytological proof of metastasis at study entry. Further inclusion criteria were: at least one bidimensionally measurable lesion, World Health Organization (WHO) performance status ≤2, normal hematology values (neutrophils ≥2 × 10 9 /l, platelets ≥100 × 10 9 /l, hemoglobin ≥10 g/dl), normal hepatic function [total bilirubin ≤1.25 times the upper limit of the institutional normal range (N), alanine and aspartate aminotransferases ≤2.5N, alkaline phosphatase ≤5N], normal renal function (creatinine ≤140 µmol/l and creatinine clearance ≥60 ml/min), and normal cardiac function as confirmed by measurement of left ventricular ejection fraction (LVEF) by echography or MUGA scan.
Patients were excluded if they had previously received chemotherapy for metastatic disease. Neoadjuvant or adjuvant chemotherapy was permitted, although prior anthracyclines were allowed only if the cumulative dose of doxorubicin or anthracycline equivalent was ≤240 mg/m 2 and a 12-month interval had elapsed since the last anthracycline adjuvant dose. Prior taxane treatment was not permitted. Hormonal therapy may have been given as adjuvant therapy or for metastatic disease provided the patient had progressive disease on study entry. Radiation therapy was allowed at sites other than those used to assess response in the study, provided a 4-week interval had elapsed since the last session. Patients must have fully recovered from any toxic effects of previous antitumor therapy.
Further exclusion criteria were a history of prior malignancies (other than curatively treated non-melanoma skin cancer or excised carcinoma in situ of the uterine cervix), known brain or leptomeningeal involvement, symptomatic grade ≥2 peripheral neuropathy, or a history of other serious illnesses or medical conditions.
Treatment schedule
Prior to randomization, which was conducted centrally using a block design method, patients were stratified for visceral involvement. Patients were randomized on study entry to receive either (i) alternating doxorubicin (A) and docetaxel (T) on a cycle-by-cycle basis for eight cycles (ATATATAT) or (ii) sequential administration of docetaxel for four cycles followed by doxorubicin for four cycles (TTTTAAAA). . If, at scheduled retreatment time, neutrophils were <1.5 × 10 9 /l or platelets were <100 × 10 patients who developed unacceptable toxicity or refused treatment during the first part of treatment (docetaxel) could proceed to the second part of treatment (doxorubicin) provided all acute toxicity had reversed.
Efficacy and safety evaluations
Baseline and study evaluations included medical history, physical examinations, radiology assessments (including homolateral mammography, chest X-ray or CT scan, abdominal ultrasound or CT scan, bone scan, and other examinations as clinically indicated), complete blood counts, assessments of liver and renal function, and cardiac monitoring by LVEF. LVEF was determined by MUGA scan or echocardiography. Tumor measurements were made at least every two cycles and responses were classified according to WHO/UICC criteria [30] . A complete response (CR) was defined as disappearance of all known disease, while a partial response (PR) was a ≥50% decrease in the size of all lesions. Complete and partial responses had to be confirmed at two evaluations not <4 weeks apart. Progressive disease (PD) was defined as a ≥25% increase in the size of at least one measurable lesion or the appearance of a new lesion. Responses were reviewed by two independent radiologists. Patients were asked to report the occurrence of any adverse event to the investigator and were monitored at least every 3 weeks (on the day before study drug infusion) for clinical and laboratory toxicity. The incidence of neuropenia was evaluated at nadir. Toxicity was graded according to National Cancer Institute Common Toxicity Criteria [31] . Complete blood counts were made weekly or every day in cases of febrile neutropenia or infection until recovery (neutrophils >1 × 10 9 /l and fever grade 0/1). LVEF was monitored after a cumulative 300 mg/m 2 dose of doxorubicin or anthracycline equivalent, and before every cycle on reaching a cumulative dose of ≥450 mg/m 2 . Irrespective of the reason for discontinuation, all patients were to be monitored during the first month after the last study drug infusion and followed up every 2 months until death to monitor tumor progression and survival.
Statistical analysis
The primary end point was determination of CR rates. Comparison of the safety profiles of the two schedules was also considered a major end point. Secondary end points were overall response rates, duration of response, time to progression, and survival. The planned sample size of 41 patients per arm was determined according to Fleming's two-stage design. It was assumed that neither treatment schedule would be of further interest if the CR rate was <5%. The sample size allowed for testing of the Null hypothesis (H0; the true CR rate is <5%) versus the Alternative hypothesis (HA; the true CR rate is >20%). As observation of a significant difference in CR rate was considered unlikely (due to the sample size), the safety comparison would assist in determining which of the two schedules would be of further interest.
Efficacy analyses, except survival, were performed on evaluable populations (patients who received at least two chemotherapy cycles and had at least one complete post-baseline tumor assessment). The overall survival analysis was performed on the intention-to-treat population [patients who had started at least one infusion of the study drug(s)]. Kaplan-Meier estimation was performed for duration of response, time to progression and survival. The duration of objective response was calculated in complete and partial responders from the start of study treatment to the time of first progression. The time to progression was determined in all patients from the start of study treatment to the time of first progression, last contact or further treatment. Survival was dated from the start of study treatment to the time of death by any cause. In case of further antitumor treatment before disease progression, time to progression was censored at the date of the last tumor assessment.
All treated patients were included in the safety analyses. Hematological analyses considered patients with at least one blood count between days 2 and 19.
Results

Patient characteristics
Of the 107 patients randomized in this trial, 106 were treated (51 with alternating therapy, 55 with sequential therapy) and were included in the safety and intention-to-treat populations. Of these, 94 patients were evaluable for tumor response (all evaluable patients had at least one measurable lesion): 48 in the alternating group and 46 in the sequential group. Reasons for non-evaluability were absence of measurable disease at baseline (n = 7) and lack of adequate tumor assessment during the study (n = 5).
The two groups had similar demographics and tumor characteristics at baseline (Table 1 ). In the intention-to-treat population, patients had a median age of 55 years, and 89% were of WHO performance status 0/1. Visceral, liver and bone involvement was reported in 82%, 51% and 47% of patients, respectively. No patients presented only bone lesions. Overall, 39% had received prior neoadjuvant or adjuvant chemotherapy but only three patients had received prior anthracyclines.
Treatment administration
Details of the number of chemotherapy cycles and cumulative chemotherapy doses are provided in Table 2 . A total of 718 chemo- therapy cycles were administered; a median of eight cycles per patient in each group. The median cumulative doses of docetaxel and doxorubicin were similar between the groups, and the median relative dose intensity was ≥0.95 for each drug with each regimen. Most cycles were administered every 3 weeks as planned (90% with the alternating regimen; 87% with the sequential regimen). Of the 35 delays in the alternating group and 47 delays in the sequential group, the majority (66% and 70%, respectively) were for no longer than 1 week. Toxicity was the most frequent reason for delay, responsible for 26 delays of the alternating regimen and 28 delays of the sequential regimen. Dose reduction was required for only nine cycles with the alternating regimen and 11 cycles with the sequential regimen, mainly because of toxicity (eight reductions with each regimen). Table 3 summarizes response rate among the evaluable patient population by prognostic factor. The objective tumor response rate was 60% [95% confidence interval (CI) 47% to 74%] in the alternating group (2% CR) and 67% (95% CI 54% to 81%) in the sequential group (7% CR). Both regimens were highly effective in patients with visceral disease or liver metastasis, and in patients who had three or more organs involved. Chemotherapynaïve patients had a higher objective response rate than those previously treated with neoadjuvant or adjuvant chemotherapy. The median duration of objective response was 47 weeks with the alternating regimen (range 37-51 weeks) and 44 weeks with the sequential regimen (range 35-52 weeks); the median time to progression was 39 weeks (range 5-68 weeks) and 38 weeks (range 0-77 weeks), respectively. With a median follow-up time of 31 months, a total of 31 deaths (61%) were observed in the alternating group and 31 (56%) in the sequential group. The median survival times were estimated at 20 and 26 months, respectively (Figure 1 ).
Tumor response
Toxicity
The two regimens were feasible and generally well tolerated. Slightly more patients in the sequential group completed the planned eight cycles of chemotherapy (69% versus 63% in the alternating group). Progressive disease was the most frequent reason for early withdrawal (16 patients in the alternating group; 12 patients in the sequential group). Only three patients in each group discontinued the study due to toxicity (isolated LVEF decrease in two patients; grade 2 infection in one patient; grade 3 hypersensitivity in one patient; uncontrolled hyperglycemia in one diabetic patient; severe asthenia concomitant with grade 3 infection, nausea and vomiting in one patient). The incidence of grade 4 neutropenia and associated toxicity is summarized in Table 4 . The majority of patients (87% overall) experienced grade 4 neutropenia, for a median of 7 days in each group (range 1-21 days in the alternating group; 1-14 days in the sequential group). Febrile neutropenia (grade 4 neutropenia concomitant with grade ≥2 fever) was more common with alternating therapy than with sequential therapy. Infection was rare (six patients had a grade 3 infection; no patient experienced a grade 4 infection). No grade 4 anemia occurred, and only one patient in the alternating group experienced grade 4 thrombocytopenia.
The incidence of non-hematological toxicity is listed in Table 5 . With both regimens, the most frequent non-hematological toxicities were alopecia, nausea, asthenia and stomatitis (each occurring in >50% of patients in each group). These toxicities were more frequent with alternating compared with sequential therapy. Grade 3 toxicity was infrequent, and only one patient experienced a grade 4 toxicity (skin toxicity with the alternating regimen). Asthenia was categorized as severe in five patients in the alternating group (10%) and in three patients in the sequential group (5%). Docetaxel-specific toxicities (i.e. nail disorders and fluid retention) were rarely severe (only one case of severe fluid retention was observed with the sequential regimen) and were never a reason for treatment discontinuation. Neurotoxicity was infrequent and mainly grade 1/2.
The incidence and severity of cardiotoxicity by cumulative dose of doxorubicin or equivalent dose of anthracyclines is summarized in Table 6 . No patient presented with congestive heart failure. LVEF decrease, as defined by Schwartz criteria (absolute decrease in LVEF ≥10 points and to a level less than or equal to the lower limit of the institutional normal range) was observed in five (10%) and two (5%) patients receiving the alternating and sequential regimens, respectively. 
Discussion
This phase II study demonstrates that both the alternating (ATATATAT) and sequential (TTTTAAAA) treatment regimens of single-agent docetaxel and doxorubicin administered every 3 weeks are feasible, active and well tolerated as first-line chemotherapy for MBC. Although the study failed to meet the primary objective (to achieve a CR rate of at least 20% in at least one treatment group), the other findings of this multicenter study are very positive. Indeed, given the overall poor patient prognosis (42% of patients had three or more organs involved; 82% of patients had visceral involvement), the objective response rates of 60% and 67% observed in the alternating and sequential groups, respectively, are very encouraging. Furthermore, both regimens also achieved good response rates in patients with visceral disease and liver metastasis, and in patients who had three or more organs involved. The median time to progression was 38 weeks in the sequential group and 39 weeks in the alternating group. The response rates observed in the present study are in line with those reported previously in studies examining the activity of docetaxel and doxorubicin as combination therapy. In phase I/II studies employing a dose of docetaxel 75 mg/m 2 and doxorubicin 50 mg/m 2 , response rates of at least 75% and 2-year survival rates of ≥50% were achieved, with excellent results observed even in patients who had received prior adjuvant therapy, or who had liver involvement or multiple sites of disease [32] [33] [34] . Furthermore, results from a recent phase III international study (TAX 306) in women with MBC reported that the combination of docetaxel 75 mg/m 2 plus doxorubicin 50 mg/m 2 achieved signifi- Patients with grade 3/4 congestive heart failure 0 0 cantly higher response rates (60% versus 47%; P = 0.012) and a significantly longer time to disease progression (P = 0.015) compared with combination therapy with doxorubicin 60 mg/m 2 plus cyclophosphamide 600 mg/m 2 [35] . These results are particularly impressive considering that the doxorubicin dosage was 20% lower in the docetaxel arm than in the cyclophosphamide arm.
The response rates achieved in the present trial with sequential and alternating docetaxel-doxorubicin regimens also compare favorably with those achieved with other anthracycline-containing combination regimens commonly used in women with first-line MBC [36] [37] [38] . However, in the absence of a well-designed phase III study of sequential and alternating docetaxel-doxorubicin therapy, caution must be employed when comparing the results of the present study with those obtained with other treatment regimens and strategies.
By adopting a sequential or alternating strategy, we were able to use the highest feasible dosages of docetaxel and doxorubicin recommended for single-agent chemotherapy (100 mg/m 2 and 75 mg/m 2 , respectively), without any apparent cumulative doselimiting toxicity. Indeed, the median number of chemotherapy cycles administered was the intended maximum of eight, and the overall median dose intensity was high in both groups. The sequential regimen appeared to be better tolerated than the alternating regimen, with slightly more patients in this group completing the planned eight chemotherapy cycles (69% versus 63%). As expected, the majority of patients experienced grade 4 neutropenia. However, in common with previous studies of single-agent docetaxel chemotherapy [12] [13] [14] [15] [16] and combination docetaxel and doxorubicin chemotherapy [21] , neutropenic episodes were usually short-lived and recovery to grade 0/1 was generally in time for the next cycle. Febrile neutropenia occurred more frequently in patients belonging to the alternating group than in those from the sequential group (14% versus 2%), although the incidence was considerably lower than that previously observed with doxorubicin-docetaxel combination chemotherapy (36%) [21] . From the first cycle, no patient required G-CSF treatment.
Both regimens in this study also had good non-hematological toxicity profiles. Severe adverse events were rare in both groups and there were no unexpected adverse events. Only one case of severe fluid retention was noted, and did not result in discontinuation of therapy. There were no clinical episodes of heart failure in the study, and asymptomatic absolute LVEF decreases of ≥10% were relatively uncommon (<8% of patients), despite a cumulative doxorubicin dose of 294 mg/m 2 and 300 mg/m 2 in the alternating and sequential groups, respectively. This finding is particularly encouraging given that paclitaxel (given by short infusion) reduces liver clearance of doxorubicin, increasing doxorubicin exposure and thereby leading to high levels of congestive heart failure (>20% in phase II trials). In contrast, docetaxel does not appear to have any effect on doxorubicin pharmacokinetics or augment anthracycline cardiotoxicity [35] .
After the initiation of this study, several other phase I/II studies evaluating the efficacy and feasibility of sequential administration of docetaxel and doxorubicin as neoadjuvant or adjuvant therapy in women with breast cancer have been reported [39] [40] [41] [42] .
Khayat et al. [42] found that administration of four cycles of docetaxel (100 mg/m 2 every 3 weeks) followed by four cycles of doxorubicin and cyclophosphamide (60/600 mg/m 2 every 3 weeks) resulted in a 71% overall response rate, with a median duration of response of 53 weeks. Another study of neoadjuvant therapy with sequential doxorubicin 75 mg/m 2 then docetaxel 100 mg/m 2 each for three cycles versus combination docetaxel 56 mg/m 2 and doxorubicin 75 mg/m 2 for four cycles found both regimens to be well tolerated and produce a high objective response rate (89% and 81%, respectively) [41] . Cresta et al. [25] recently reported results from a randomized phase II study that compared alternating, sequential and simultaneous combination of docetaxel and doxorubicin as first-line chemotherapy in 121 patients with MBC. The overall response rate (57%, 67% and 66%, respectively) and time to disease progression (34, 33 and 36 weeks, respectively) were similar across all three treatment arms. Interestingly, the response rate for the sequential arm is identical to that obtained in the sequential arm of our study (67%), and further mirrors the present study in that it was slightly higher than the rate obtained for the alternating arm (60% for the current study and 57% for the study of Cresta et al. [25] ). Febrile neutropenia (22%), grade 3-4 infections (2%) and grade 3-4 stomatitis (12%) were more common with the combination regimen. In addition, four episodes of congestive heart failure occurred in the combination arm, attributed to the higher cumulative dose of doxorubicin (480 mg/m 2 ). Cresta et al. concluded that either the sequential or alternating schedules were viable first-line treatments for MBC [25] . A number of randomized phase III trials are now underway to further define the role of sequential docetaxeldoxorubicin chemotherapy in early breast cancer patients, and their results are eagerly awaited.
In conclusion, the efficacy and tolerability of simultaneous combination therapy with docetaxel plus doxorubicin in MBC is well established. The present phase II study suggests that alternating and sequential regimens of these two cytotoxic agents are viable alternatives to simultaneous combination therapy in this setting, with the sequential regimen achieving slightly higher response rates and improved tolerability compared with the alternating regimen. Phase III studies are warranted to validate these findings.
